FASUDIL

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H17N3O2S
Molecular Weight	291.369
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O=S(=O)(N1CCCNCC1)C2=CC=CC3=C2C=CN=C3

InChI

InChIKey=NGOGFTYYXHNFQH-UHFFFAOYSA-N

InChI=1S/C14H17N3O2S/c18-20(19,17-9-2-6-15-8-10-17)14-4-1-3-12-11-16-7-5-13(12)14/h1,3-5,7,11,15H,2,6,8-10H2

HIDE SMILES / InChI

Molecular Formula	C14H17N3O2S
Molecular Weight	291.369
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://library.corporate-ir.net/library/17/177/177285/items/203435/FasudilfactsheetJune262006.pdf

Fasudil is a potent Rho kinase inhibitor, which was developed by Asahi Kasei. The drug is used in Asia for the prevention of cerebral vasospasm in patients with subarachnoid hemorrhage.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Rho-associated protein kinase 6 Target ID: CHEMBL2111459 Sources: http://library.corporate-ir.net/library/17/177/177285/items/203435/FasudilfactsheetJune262006.pdf	Inhibitor 8228		0.4 µM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cerebral vasospasm 9 Sources: http://www.pharm.or.jp/eng/126th/data/AL07.pdf	Preventing		Approved 8360	ERIL Approved Use Improvement of cerebral vasospasm and cerebral ischemic symptoms associated with cerebral vasospasm after subarachnoid hemorrhage.

PubMed

Title	Date	PubMed
Combined administration of Fasudil hydrochloride and nitroglycerin for treatment of cerebral vasospasm.	2001	11563287
Effect of Fasudil HCl, a protein kinase inhibitor, on cerebral vasospasm.	2001	11563286
Microtubule disruption modulates the Rho-kinase pathway in vascular smooth muscle.	2001	11519742
Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage.	2001 Aug 10	11531167
Hydroxyfasudil, an active metabolite of fasudil hydrochloride, relaxes the rabbit basilar artery by disinhibition of myosin light chain phosphatase.	2001 Jul	11435800
Dependency of detrusor contractions on calcium sensitization and calcium entry through LOE-908-sensitive channels.	2001 Sep	11522599
Involvement of Rho-kinase in vascular remodeling caused by long-term inhibition of nitric oxide synthesis in rats.	2001 Sep 7	11553365
Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina.	2002 Apr 2	11927519
RhoA kinase and protein kinase C participate in regulation of rabbit stomach fundus smooth muscle contraction.	2002 Dec	12429570
Membrane depolarization-induced contraction of rat caudal arterial smooth muscle involves Rho-associated kinase.	2002 Jun 1	12023886
Comparison of angiotensin II (Ang II) effects in the internal anal sphincter (IAS) and lower esophageal sphincter smooth muscles.	2002 Mar 22	12002807
Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study.	2002 Nov	12409984
Occupation of the prostaglandin E2-type 1 receptor increases rat atrial contractility via a Y-27632-sensitive pathway.	2002 Sep	12428681
Nitric oxide-induced motility in aortic smooth muscle cells: role of protein tyrosine phosphatase SHP-2 and GTP-binding protein Rho.	2002 Sep 6	12215487
Functional roles of the rho/rho kinase pathway and protein kinase C in the regulation of cerebrovascular constriction mediated by hemoglobin: relevance to subarachnoid hemorrhage and vasospasm.	2003 Apr 18	12637369
Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats.	2003 Dec	14633123
Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm.	2003 Jan 1	12570938
A possible role of RhoA/Rho-kinase in experimental spinal cord injury in rat.	2003 Jan 3	12480155
Protein kinase C is necessary for recovery from the thyrotropin-releasing hormone-induced r-ERG current reduction in GH3 rat anterior pituitary cells.	2003 Mar 15	12562894
Expression of Rho-kinase and its functional role in the contractile activity of the mouse vas deferens.	2003 Oct	14504141
[Development of drug delivery system for intrathecal administration and its therapeutic effect on cerebral vasospasm and ischemia].	2004 Aug	15297723
Involvement of Rho-kinase in cold ischemia-reperfusion injury after liver transplantation in rats.	2004 Aug 15	15316365
Involvement of RhoA and possible neuroprotective effect of fasudil, a Rho kinase inhibitor, in NMDA-induced neurotoxicity in the rat retina.	2004 Aug 20	15262212
Differential effects of Rho-kinase inhibition on artery wall mass and remodeling.	2004 Jan	14718843
Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice.	2004 Jan 9	14615290
Involvement of RhoA and Rho kinase in neutrophil-stimulated endothelial hyperpermeability.	2004 Mar	14630629
Rho kinase inhibition initiates apoptosis in human airway epithelial cells.	2004 Mar	12933355
Rho kinase mediates cold-induced constriction of cutaneous arteries: role of alpha2C-adrenoceptor translocation.	2004 May 28	15087420
Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats.	2004 Sep	15311108
Stent implantation activates RhoA in human arteries: inhibitory effect of rapamycin.	2005 Jan-Feb	15627783
Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes.	2005 Jul	15860745
Fasudil prevents KATP channel-induced improvement in postischemic functional recovery.	2005 Jun	15695558
Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension.	2005 Mar	15710736
Negative regulation of RhoA/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats.	2005 May	15834290

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dosage is 30 mg fasudil hydrochloride should be diluted in 50-100 mL solution and administered by intravenous infusion over 30 minutes 2-3 times daily.

Route of Administration: Intravenous

In Vitro Use Guide

The rat aortic rings were contracted by KCl; when the contraction reached a plateau, fasudil was added at concentrations from 10(-9) to 10(-5) M. The relaxation IC50 was 0.74 uM. When rabbit aortic rings were used, IC50 values were 37,15 uM and 27,54 uM for KCl and Methoxamine-induced contraction, respectively.

Substance Class	Chemical Created by `admin` on `Thu Jul 06 22:21:15 UTC 2023` Edited by `admin` on `Thu Jul 06 22:21:15 UTC 2023`
Record UNII	Q0CH43PGXS
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FASUDIL

Official Name

English

AT-877

Code

English

HA 1077

Code

English

1-(5-ISOQUINOLINESULFONYL)HOMOPIPERAZINE

Systematic Name

English

HA-1077

Code

English

HEXAHYDRO-1-(5-ISOQUINOLYLSULFONYL)-1H-1,4-DIAZEPINE

Systematic Name

English

ZK-258594

Code

English

N-(5-ISOQUINOLINESULFONYL)-1,4-PERHYDRODIAZEPINE

Common Name

English

fasudil [INN]

Common Name

English

ISOQUINOLINE, 5-((HEXAHYDRO-1H-1,4-DIAZEPIN-1-YL)SULFONYL)-

Systematic Name

English

FASUDIL [MI]

Common Name

English

AT 877

Code

English

NSC-759827

Code

English

5-((HEXAHYDRO-1H-1,4-DIAZEPIN-1-YL)SULFONYL)ISOQUINOLINE

Systematic Name

English

Fasudil [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-ATC

C04AX32